Recombinant Mouse Anti-TrkA Antibody scFv Fragment (MNAC13) (CAT#: PABX-182-S (P))

Figure 1 Functional Assay OF MNAC13

Antiallodynic effects measured with a dynamic plantar aesthesiometer after four i.p. injections of 50 μg per mouse MNAC13 (from day 3 to day 6 after ligation of the sciatic nerve) in CCI mice tested for 14 days (IgG, n = 7; MNAC13, 50 μg per mouse, n = 5) (A) and after eight i.p. injections of 30 or 70 μg per mouse MNAC13 (from day 3 to day 10 after ligation of the sciatic nerve) in CCI mice tested from day 3 up to day 31 (B). (IgG, n = 11; MNAC13, 30 μg per mouse, n = 8; MNAC13, 70 μg per mouse, n = 12.) Black arrows represent the antibody i.p. administrations. BL (baseline) refers to mechanical threshold before operation. Black lines represent mechanical thresholds of sham-operated controls (n = 6). Data are presented as means ± SEM. *, P<0.05; **, P<0.01 vs. IgG-injected mice (Tukey/Kramer).

Ugolini, G., Marinelli, S., Covaceuszach, S., Cattaneo, A., & Pavone, F. (2007). The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proceedings of the National Academy of Sciences, 104(8), 2985-2990.

Figure 2 The result of a FACS analysis on 3T3 TrkA+ cells

MNAC13 recognises the TrkA receptor on living cells. Balb/C 3T3 or TrkA+ Balb/C 3T3 cells were incubated with MNAC13 antibody and subjected to FACS analysis.

Figure 3 SPR analysis of MNAC13 binding to TrkA and p75 receptor

MNAC13 does not bind to the p75 receptor: Surface Plasmon Resonance experiments were performed by using a BIACore instrument (BIACore, Uppsala, Sweden).

Ugolini, G., Marinelli, S., Covaceuszach, S., Cattaneo, A., & Pavone, F. (2007). The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proceedings of the National Academy of Sciences, 104(8), 2985-2990.

Figure 4 Phosphorylation Assay of TrkA affected by MNAC13

Western blot results showing that MNAC13 leads to reduction of phospho-TrkA levels after NGF stimulation in mouse 3T3 cells overexpressing TrkA. Antibodies were used at two different concentrations: 300 μg/ml (h) and 200 μg/ml (l).

Ugolini, G., Marinelli, S., Covaceuszach, S., Cattaneo, A., & Pavone, F. (2007). The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proceedings of the National Academy of Sciences, 104(8), 2985-2990.

Figure 5 Inhibition of MNAC13

Western blot results showing that MNAC13 leads to inhibition of NGF-dependent phosphorylation of the PLCγ1 adaptor protein in mouse 3T3 cells overexpressing TrkA. Antibodies were used at two different concentrations: 300 μg/ml (h) and 200 μg/ml (l).

Ugolini, G., Marinelli, S., Covaceuszach, S., Cattaneo, A., & Pavone, F. (2007). The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proceedings of the National Academy of Sciences, 104(8), 2985-2990.